Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1in treating su ...
Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gang ...